

TOPAMAX® (topiramate)

Dosing - Discontinuation or Withdrawal of TOPAMAX Therapy

SUMMARY

- In patients with or without a history of seizures or epilepsy, antiepileptic drugs, including TOPAMAX®, should be gradually withdrawn to minimize the potential for seizures or increased seizure frequency. In situations where rapid withdrawal of TOPAMAX® is medically required, appropriate monitoring is recommended.¹

PRODUCT LABELING

Please refer to the following sections of the Full Prescribing Information¹ that are relevant to your inquiry: WARNINGS AND PRECAUTIONS and CLINICAL STUDIES.

As stated in the CLINICAL STUDIES section:

Epilepsy

In clinical trials for epilepsy, daily dosages were decreased in weekly intervals by 50 to 100 mg/day in adults and over a 2- to 8- week period in pediatric patients; transition was permitted to a new antiepileptic regimen when clinically indicated.

Migraine

For patients withdrawing from TOPAMAX®, daily dosages were decreased in weekly intervals by 25 to 50 mg/day.

REFERENCES

1. TOPAMAX (topiramate) [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-af7139e0-ca6d-4cd0-a13f-3ba15f0e8d89.